Market Assessment - Strategic assessment of injectable, in situ gelling materials for ocular drug delivery

市场评估 - 用于眼部药物输送的可注射原位胶凝材料的战略评估

• 批准号: 556937-2020
• 负责人: Sheardown, Heather
• 金额: $ 1.09万
• 依托单位: McMaster University
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=706389
• 关键词: Market; Assessment; Strategic; assessment; injectable

Diseases in the eye are becoming increasingly common as the population ages; however, they remain notoriously difficult to treat. For instance, age-related macular degeneration (AMD) affects over 1.4 million Canadians and is the leading cause of vision loss in Canada. While the advent of anti-VEGF agents, a specific class of drugs, has significantly improved the prognosis and outcomes for many of these patients, they require intraocular injections every one to two months to maintain their effectiveness. Similarly, glaucoma, the second leading cause of blindness, requires patients to adhere to a challenging regime of eye drops multiple times each day, causing patients to struggle with compliance. Yet, if these conditions progress to vision loss, patients have been shown to require greater assistance with daily activities, suffer high incidences of depression and anxiety, and have twice the risk of falls; this all results in a substantial decrease in their quality of life. We propose a new delivery system that would work with different therapeutics for a variety of conditions. This would reduce treatments from monthly to bi-annually, increasing both safety and convenience for patients and reducing the burden on the healthcare system. We request funds to complete a Market Assessment to determine which ocular disease condition is best suited to initial development, which will allow us to then create a business plan for successful technology transfer and commercialization.

随着人口老龄化，眼部疾病正变得越来越常见；然而，它们仍然是出了名的难以治疗。例如，老年性黄斑变性(AMD)影响着超过140万加拿大人，是加拿大视力丧失的主要原因。虽然抗血管内皮生长因子药物的出现显著改善了许多此类患者的预后和结局，但它们需要每一到两个月进行一次眼内注射才能保持疗效。同样，青光眼是导致失明的第二大原因，要求患者每天多次坚持使用具有挑战性的眼药水，导致患者难以遵从性。然而，如果这些情况进展到视力丧失，患者在日常活动中需要更多的帮助，抑郁和焦虑的发生率很高，跌倒的风险是前者的两倍；所有这些都会导致他们的生活质量大幅下降。我们提出了一种新的递送系统，它将在不同的条件下与不同的疗法一起工作。这将把治疗从每月减少到一年两次，增加了患者的安全性和便利性，并减轻了医疗系统的负担。我们要求资金完成市场评估，以确定哪种眼病最适合初步开发，这将使我们能够为成功的技术转让和商业化制定商业计划。